FOIA to FDA for Analyses or Assessments Used by FDA During Deliberations Over Aduhelm

FOIA request to the U.S. Food and Drug Administration seeking any final analyses or assessments used by FDA during deliberations over the approval of Aduhelm (aducanumab), an AlzheimerÕs drug produced by Biogen. HHS-FDA-22-0117